Danaher Co. (NYSE:DHR) Shares Sold by Oak Ridge Investments LLC

Oak Ridge Investments LLC cut its stake in Danaher Co. (NYSE:DHR - Free Report) by 92.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,904 shares of the conglomerate's stock after selling 22,331 shares during the quarter. Oak Ridge Investments LLC's holdings in Danaher were worth $437,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Decker Retirement Planning Inc. bought a new position in shares of Danaher during the fourth quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. purchased a new stake in Danaher in the third quarter worth $40,000. FSA Wealth Management LLC purchased a new stake in shares of Danaher during the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC bought a new position in shares of Danaher in the third quarter worth about $55,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Danaher stock traded down $3.49 during mid-day trading on Monday, reaching $238.41. 3,044,734 shares of the company traded hands, compared to its average volume of 2,640,177. Danaher Co. has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The firm's fifty day moving average is $234.85 and its two-hundred day moving average is $253.51. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The company has a market capitalization of $172.20 billion, a price-to-earnings ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm's quarterly revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $2.02 EPS. On average, equities research analysts expect that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher's dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Guggenheim began coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a "buy" rating and a $275.00 price objective for the company. KeyCorp increased their price objective on Danaher from $290.00 to $310.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 23rd. Wolfe Research raised Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price for the company in a research report on Thursday, October 31st. Robert W. Baird dropped their price target on Danaher from $278.00 to $277.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 23rd. Finally, Raymond James decreased their price objective on Danaher from $310.00 to $300.00 and set an "outperform" rating for the company in a report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.